See more : Metcash Limited (MCSHF) Income Statement Analysis – Financial Results
Complete financial analysis of Genprex, Inc. (GNPX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genprex, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bausch + Lomb Corporation (BLCO) Income Statement Analysis – Financial Results
- OPY Acquisition Corp. I (OHAAU) Income Statement Analysis – Financial Results
- Live Oak Bancshares, Inc. (LOB) Income Statement Analysis – Financial Results
- G-Resources Group Limited (1051.HK) Income Statement Analysis – Financial Results
- ROHM Co., Ltd. (ROHCY) Income Statement Analysis – Financial Results
Genprex, Inc. (GNPX)
About Genprex, Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 15.00K | 23.83M | 22.53K | 22.78K | 13.07K | 5.89K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -15.00K | -23.83M | -22.53K | -22.78K | -13.07K | -5.89K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 17.62M | 11.51M | 8.61M | 7.30M | 1.97M | 971.43K | 289.93K | 354.88K | 201.96K |
| General & Administrative | 13.44M | 12.30M | 10.97M | 10.64M | 8.70M | 11.39M | 3.02M | 3.78M | 865.70K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.44M | 12.30M | 10.97M | 10.64M | 8.70M | 11.39M | 3.02M | 3.78M | 865.70K |
| Other Expenses | 0.00 | 25.58K | 22.53K | 22.78K | 13.07K | 5.89K | 3.24K | 0.00 | 0.00 |
| Operating Expenses | 31.06M | 23.83M | 19.60M | 17.96M | 10.68M | 12.36M | 3.31M | 4.13M | 1.07M |
| Cost & Expenses | 31.08M | 23.83M | 19.60M | 17.96M | 10.68M | 12.36M | 3.31M | 4.13M | 1.07M |
| Interest Income | 215.11K | 90.10K | 5.13K | 18.81K | 27.91K | 29.18K | 80.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.98K | 1.89K | 0.00 | 0.00 |
| Depreciation & Amortization | 15.00K | 25.58K | 22.53K | 22.78K | 13.07K | 5.89K | 3.24K | 862.00 | 2.06K |
| EBITDA | -31.06M | -23.81M | -20.65M | -17.94M | -10.64M | -12.33M | -3.31M | -4.13M | -1.07M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -31.08M | -23.83M | -19.60M | -17.96M | -10.68M | -12.36M | -3.31M | -4.13M | -1.07M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 215.11K | 90.10K | 5.13K | 18.81K | 27.90K | -8.80K | -1.81K | 0.00 | 0.00 |
| Income Before Tax | -30.86M | -23.74M | -19.60M | -17.94M | -10.65M | -12.37M | -3.31M | -4.13M | -1.07M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 5.72M | -5.13K | -18.81K | -130.89K | 29.18K | 80.00 | 0.00 | 0.00 |
| Net Income | -30.86M | -29.46M | -19.59M | -17.92M | -10.65M | -12.37M | -3.31M | -4.13M | -1.07M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -22.58 | -24.59 | -16.64 | -20.18 | -26.64 | -35.97 | -11.55 | -15.30 | -23.25 |
| EPS Diluted | -22.56 | -24.58 | -16.64 | -20.18 | -26.59 | -35.94 | -11.53 | -15.26 | -22.93 |
| Weighted Avg Shares Out | 1.37M | 1.20M | 1.18M | 888.00K | 400.00K | 344.00K | 287.00K | 270.00K | 46.00K |
| Weighted Avg Shares Out (Dil) | 1.37M | 1.20M | 1.18M | 888.07K | 400.68K | 344.28K | 287.50K | 270.87K | 46.66K |
Genprex shares rise as FDA grants third Fast Track Designation for small cell lung cancer therapeutic REQORSA
Genprex, Inc. (NASDAQ:GNPX) shares moved higher in pre-market trading after the clinical-stage gene therapy company announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its therapeutic REQORSA in combination with Genentech's Tecentriq in...
Genprex (GNPX) Up on Advancing Early-Stage NSCLC Study
Genprex's (GNPX) shares rise due to the advancement of early-stage Acclaim-1 study for patients with late-stage non-small cell lung cancer.
Genprex wins approval to advance Phase 2 expansion of Acclaim-1 trial of REQORSA combined with Tagrisso in advanced non-small cell lung cancer
Genprex Inc. revealed that it has completed the Phase 1 portion of the Acclaim-1 Phase 1/2 clinical trial evaluating REQORSA Immunogene therapy combined with Tagrisso in late-stage non-small cell lung cancer (NSCLC), and the Safety Review Committee (SRC) has approved forging...
Genprex says positive data from Acclaim-1 clinical trial to be published at 2023 ASCO meeting
Genprex Inc. (NASDAQ:GNPX) said positive data from the Phase 1 portion of its Acclaim-1 clinical trial evaluating REQORSA Immunogene Therapy in combination with Tagrisso in late-stage non-small cell lung cancer (NSCLC) will be published in an abstract at the 2023 American...
Penny Stocks To Buy? 10 Under $1 To Watch This Week
Penny stocks under $1 to watch this week. The post Penny Stocks To Buy?
Genprex showcases unique potential of nonparticle delivery system at cancer conference; shares rise
A research collaborator of Genprex Inc delivered a presentation highlighting the company's non-viral ONCOPREX Nanoparticle Delivery System, the company announced. Investors liked what they saw, as shares climbed 5% to $1.
Genprex encouraged by latest reports on novel tumor suppressor
Genprex, Inc. (NASDAQ:GNPX) said independent researchers have reported that the tumor suppression gene used in its lead drug candidate REQORSA functions as a novel tumor suppressor for glioblastoma. Genprex CEO Rodney Varner said the research supports the growing body of...
Genprex to Present at Bioprocessing Summit Conference
Genprex Chief Manufacturing and Technology Officer to Provide Insight on Manufacturing Gene Therapies AUSTIN, Texas , March 13, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for...
Genprex announces $4M direct offering with single, healthcare-focused institutional investor
Genprex Inc. said it has entered into a securities purchase agreement with a single, healthcare-focused institutional investor for gross proceeds of approximately $4 million.
Genprex (GNPX) Stock Moves on Promising Diabetes Treatment Data
Genprex (NASDAQ: GNPX ) stock is on the move Thursday after providing an update on a study of its diabetes treatment. That positive news comes from a trial of gene therapy for the treatment of Type 1 diabetes.
Source: https://incomestatements.info
Category: Stock Reports